| Cross-sectional case-control studies  

COVID-19 BREAKING NEWS: CROSS-SECTIONAL CASE CONTROL STUDIES – JUNE 2022

Our editors' pick of Covid-related cross-sectional case control studies from the scientific press for June 2022.

 

Read on for our pick of Covid-related cross-sectional case control studies from the scientific press for June 2022:

Risk of COVID-19 Infection and of Severe Complications Among People With Epilepsy: A Nationwide Cohort Study
The goal of this work was to evaluate whether patients with epilepsy were more susceptible to COVID-19 infection and at greater risk of severe complications when infected with COVID-19 compared with patients without epilepsy. The authors included participants who underwent at least 1 severe acute respiratory syndrome coronavirus 2 real-time reverse-transcription PCR test between January 1 and June 4, 2020, from the Korean nationwide COVID-19 dataset. Epilepsy was defined according to the presence of diagnostic code in health claims data before the COVID-19 diagnosis. To investigate the association between epilepsy and the susceptibility for or severe complications of COVID-19, a 1:6 ratio propensity score matching (PSM) and logistic regression analysis were performed. Severe complications with COVID-19 infection were defined as a composite of the incidence of mechanical ventilation, intensive care unit admission, and death within 2 months after COVID-19 diagnosis. Among 212,678 study participants who underwent a COVID-19 test, 3,919 (1.8%) had a history of epilepsy. After PSM, there was no significant difference in COVID-19 PCR positivity according to epilepsy history (odds ratio [OR] 0.86, 95% CI 0.67-1.11). Of the 7,713 individuals with confirmed COVID-19 infection, 72 (0.9%) had a history of epilepsy. Among the patients with COVID-19, severe complications occurred in 444 (5.8%) individuals. After PSM, the presence of epilepsy was associated with the occurrence of severe complications after COVID-19 infection (OR 2.05, 95% CI 1.04-4.04). Mortality after COVID-19 infection did not differ according to the presence of epilepsy history (OR 1.55, 95% CI 0.65-3.70). The authors concluded that the presence of epilepsy was not associated with increased susceptibility to COVID-19 infection or mortality related to the infection. However, there was an increased risk of severe complications with COVID-19 in patients with epilepsy; therefore, careful management and monitoring may be necessary.
Yoo J, Kim JH, Jeon J, Kim J, Song TJ. Risk of COVID-19 Infection and of Severe Complications Among People With Epilepsy: A Nationwide Cohort Study. Neurology. 2022 May 10;98(19):e1886-e1892. doi: 10.1212/WNL.0000000000200195.